Agile Therapeutics (NASDAQ:AGRX) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Agile Therapeutics (NASDAQ:AGRX) in a research report issued to clients and investors on Saturday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Separately, Maxim Group reaffirmed a “hold” rating on shares of Agile Therapeutics in a report on Monday, March 18th.

Agile Therapeutics Stock Performance

Shares of AGRX opened at $0.38 on Friday. The company has a market cap of $2.61 million, a price-to-earnings ratio of -0.04 and a beta of 1.42. The stock has a fifty day moving average price of $0.64 and a two-hundred day moving average price of $1.44. Agile Therapeutics has a 52-week low of $0.20 and a 52-week high of $7.00.

Institutional Investors Weigh In On Agile Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in AGRX. Armistice Capital LLC grew its position in shares of Agile Therapeutics by 10.2% during the 4th quarter. Armistice Capital LLC now owns 108,000 shares of the specialty pharmaceutical company’s stock worth $211,000 after buying an additional 10,000 shares during the period. State Street Corp acquired a new position in shares of Agile Therapeutics in the 2nd quarter valued at $32,000. BlackRock Inc. boosted its position in shares of Agile Therapeutics by 1.1% in the 1st quarter. BlackRock Inc. now owns 1,523,758 shares of the specialty pharmaceutical company’s stock worth $319,000 after purchasing an additional 16,104 shares during the last quarter. Vanguard Group Inc. acquired a new stake in shares of Agile Therapeutics during the fourth quarter worth $40,000. Finally, Jane Street Group LLC bought a new stake in Agile Therapeutics in the second quarter valued at about $108,000. 10.92% of the stock is owned by institutional investors and hedge funds.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc, a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.